ImageneBio, Inc.(IMA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,857 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
IMA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ImageneBio, Inc. (IMA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMA at 3.9/100 on a 32-signal composite quality model, placing it at rank #2,857 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (0.3) and revenue growth (1.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ImageneBio, Inc. reports net income of $-10.6M, free cash flow of $-14.8M. Top institutional holders of IMA by reported 13-F value include BVF /IL, Blue Owl Capital Holdings, Cable Car Capital,, based on the most recent SEC filings. IMA trades on the Nasdaq exchange and files with the SEC under CIK 1835579. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ImageneBio, Inc. directly from SEC EDGAR. ImageneBio, Inc.'s 13F Pro composite quality score has ranged between 4 and 23 since 2026, currently 3.9 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.
Net Income
Q1 2026
$-10.6M
Free Cash Flow
Q1 2026
$-14.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-77.1% YoYNet Income
-24.0% YoYOperating Income
-30.9% YoYEPS (Diluted)
+56.4% YoYTotal Assets
+860.8% YoYTotal Debt
-100.0% YoYOp. Cash Flow
-124.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $800.0K -77.1% | $3.5M -61.8% | $9.2M -41.3% | $15.6M -49.6% | $31.0M | — |
| Net Income | $-45.3M -24.0% | $-36.6M +46.4% | $-68.2M +0.9% | $-68.8M -101.6% | $-34.1M | — |
| Operating Income | $-48.5M -30.9% | $-37.0M +50.9% | $-75.4M -6.4% | $-70.9M -107.7% | $-34.1M | — |
| EPS (Diluted) | $-9.64 +56.4% | $-22.10 -1255.8% | $-1.63 +14.2% | $-1.90 -55.7% | $-1.22 | — |
| Total Assets | $153.0M +860.8% | $15.9M -91.7% | $192.1M +11.5% | $172.3M -30.5% | $247.9M | — |
| Total Debt | $0.00 -100.0% | $7.5M | — | — | — | — |
| Operating Cash Flow | $-47.8M -124.4% | $-21.3M +73.3% | $-79.7M -7.6% | $-74.1M -23.0% | $-60.3M | — |
Get alerted when IMA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ImageneBio, Inc. including:
Top Institutional Holders of IMA
BVF INC/IL
$5.6M1,110,002 shBlue Owl Capital Holdings LP
$4.8M959,337 shCable Car Capital, LP
$3.8M754,749 shOmega Fund Management, LLC
$2.3M455,361 shORBIMED ADVISORS LLC
$1.9M378,556 shRTW INVESTMENTS, LP
$1.7M334,445 shVANGUARD CAPITAL MANAGEMENT LLC
$1.6M325,155 shBML Capital Management, LLC
$1.0M200,730 shBlackRock, Inc.
$646.1K129,214 shCITADEL ADVISORS LLC
$621.7K124,345 sh
| Fund | Value | Shares |
|---|---|---|
| BVF INC/IL | $5.6M | 1,110,002 |
| Blue Owl Capital Holdings LP | $4.8M | 959,337 |
| Cable Car Capital, LP | $3.8M | 754,749 |
| Omega Fund Management, LLC | $2.3M | 455,361 |
| ORBIMED ADVISORS LLC | $1.9M | 378,556 |
| RTW INVESTMENTS, LP | $1.7M | 334,445 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.6M | 325,155 |
| BML Capital Management, LLC | $1.0M | 200,730 |
| BlackRock, Inc. | $646.1K | 129,214 |
| CITADEL ADVISORS LLC | $621.7K | 124,345 |
More Healthcare Companies
View all Healthcare →Put IMA on your watchlist
Track score changes the day ImageneBio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IMA a good stock to buy?
13F Pro's AI-powered analysis of ImageneBio, Inc. (IMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMA are available on the IMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own IMA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ImageneBio, Inc.'s investment landscape.